MapLight Therapeutics, Inc.
NASDAQ:MPLTBiotechnology
+$0.39 today
- Market cap
- $283.41M
- Beta
- 2.65
- P/E (TTM)
- -2.8
- EPS (TTM)
- -$4.41
Volume 0.42M
Average 0.73M
MPLT Operating Margin
Operating income as a percentage of revenue, showing the profitability of core operations.
Operating Margin history
Percent of revenue · from the income statement
No Operating Margin data reported for this period type.
Operating Margin vs competitors
How MPLT compares with its peers on the latest reported figures
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | -39.9% | +137.2 pp | +414.9 pp | |
RAPPRapport Therapeutics, Inc. Common Stock | LTM Mar 2026 | -611.0% | — | — |
| LTM Mar 2026 | -670.2% | +9733.9 pp | +3111.2 pp | |
| FY2025 | — | — | — | |
DFTXDefinium Therapeutics, Inc. | FY2025 | — | — | — |
LBRXLB Pharmaceuticals Inc Common Stock | FY2025 | — | — | — |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
NMRANeumora Therapeutics, Inc. Common Stock | FY2025 | — | — | — |
| Peer median (excluding MPLT) | -611.0% | +4935.6 pp | +1763.1 pp | |
Competitors are the stored peer set for MPLT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 |
| Cost of Revenue | 574K | 556K | 701K | 578K |
| Gross Profit | (574K) | (556K) | (701K) | (578K) |
| Gross Margin | — | — | — | — |
| Research & Development | 26.57M | 49.12M | 67.82M | 137.77M |
| Selling, General & Admin | 4.1M | 7.61M | 14.42M | 30.73M |
| Operating Expenses | 30.67M | 56.73M | 82.25M | 168.51M |
| Depreciation & Amortization | 574K | 556K | 701K | 578K |
| EBITDA | (29.44M) | (55.15M) | (76.88M) | (160.57M) |
| EBITDA Margin | — | — | — | — |
| Operating Income | (31.25M) | (57.28M) | (82.95M) | (169.08M) |
| Operating Margin | — | — | — | — |
| Interest Income | 429K | 1.1M | 4.5M | 5.52M |
| Interest Expense | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 1.23M | 1.57M | 5.37M | 7.93M |
| Income Before Tax | (30.02M) | (55.71M) | (77.58M) | (161.15M) |
| Pre-Tax Margin | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 |
| Net Income | (30.02M) | (55.71M) | (77.58M) | (161.15M) |
| Net Margin | — | — | — | — |
| EPS (Basic) | (0.72) | (1.34) | (1.87) | (3.66) |
| EPS (Diluted) | (0.72) | (1.34) | (1.87) | (3.66) |
| Weighted Avg Shares | 41.43M | 41.43M | 41.43M | 44.02M |
| Weighted Avg Shares (Diluted) | 41.43M | 41.43M | 41.43M | 44.02M |
MapLight Therapeutics, Inc.
NASDAQ:MPLT
Intrinsic Alpha fair value
Locked
Current Price
$6.65
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.